Collect Product
Product Details
Synonyms
IL33, DV27, C9ORF26, IL1F11, NFHEV, DKFZp586H0523, DVS27, NFEHEV, RP11-575C20.2
Source
Mouse IL-33, His Tag (IL3-M5245) is expressed from human 293 cells (HEK293). It contains AA Ser 109 - Ile 266 (Accession # Q8BVZ5-1).
Request for sequenceMolecular Characterization
Other Tags and Version Biotin & Other Labeled Version
This protein carries a polyhistidine tag at the N-terminus.
The protein has a calculated MW of 19.6 kDa. The protein migrates as 20-30 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
Purity
>90% as determined by SDS-PAGE.
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Kunden haben auch angesehen
Data Display
SDS-PAGE
Mouse IL-33, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).
Bioactivity-ELISA
Immobilized Mouse IL-33, His Tag (Cat. No. IL3-M5245) at 10 μg/mL (100 μL/well) can bind Mouse IL-1RL1, Fc Tag (Cat. No. IL1-M5259) with a linear range of 0.001-0.156 μg/mL (QC tested).
Protocol
User Reviews Publish Comment
Background Introduction
Frontier Progress
Drug Development Progress- English Name：
Interleukin-33
- Category：
- Listed Drugs Count：
0 Details
- Clinical Drugs Count：
9 Details
- Highest R&D Stage：
Phase 3 Clinical
Contact Us
Drug Candidate Licensing
